导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.10% | 2445/4773 |
| 近一周 | -1.59% | 2342/5465 |
| 近一月 | -3.38% | 2447/5421 |
| 近一季 | -5.96% | 2230/5231 |
| 近半年 | -1.98% | 1974/4920 |
| 近一年 | 2.12% | 2343/4394 |
| 近两年 | 49.83% | 1508/2954 |
| 近三年 | 29.25% | 1112/2253 |
| 成立以来 | 87.00% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.39% 3176/4961 |
12.58% 2155/5312 |
- - |
- - |
| 2025 | 20.80% 2088/4813 |
-0.90% 2448/3635 |
2.02% 1943/4076 |
19.42% 2147/4524 |
0.06% 2252/4813 |
| 2024 | 14.60% 1033/3463 |
2.19% 807/2808 |
-1.63% 1085/3014 |
16.71% 1371/3129 |
-2.33% 2043/3463 |
| 2023 | -9.31% 1149/2656 |
4.54% 924/2280 |
-4.47% 1183/2385 |
-3.22% 871/2515 |
-6.16% 1650/2655 |
| 2022 | -17.84% 635/2207 |
-14.50% 957/1919 |
7.78% 428/2016 |
-12.41% 705/2113 |
1.79% 1138/2208 |
| 2021 | 5.90% 530/1822 |
-2.46% 647/1255 |
9.18% 582/1330 |
-3.08% 611/1466 |
2.61% 554/1822 |
| 2020 | 45.09% 220/1250 |
-6.40% 482/1028 |
17.77% 362/1067 |
15.26% 226/1164 |
14.18% 293/1184 |
| 2019 | 41.89% 227/1092 |
26.93% 371/754 |
-0.14% 226/804 |
3.10% 271/850 |
8.58% 304/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.47% 298/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华泰MSCI中国A股国际通ETF VS. 长安沪深300非周期A(740101) |